Holen Sie sich die Stockscreener-App
4.89
0.20%
-0.01
Handel nachbörslich:
4.80
-0.09
-1.84%
Annexon Inc Aktie (ANNX) Neueste Nachrichten
Jamie Dananberg Sells 5,290 Shares of Annexon (NASDAQ:ANNX) Stock - MarketBeat
Insider Selling: Annexon (NASDAQ:ANNX) EVP Sells 5,290 Shares of Stock - MarketBeat
Annexon (NASDAQ:ANNX) EVP Sells $40,149.27 in Stock - MarketBeat
Annexon (NASDAQ:ANNX) CFO Sells $40,118.61 in Stock - MarketBeat
Will Annexon Inc benefit from government policyTrade Volume Summary & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Aug Spikes: Will Annexon Inc benefit from government policyJuly 2025 PreEarnings & Technical Pattern Based Signals - baoquankhu1.vn
Published on: 2026-02-21 08:39:55 - baoquankhu1.vn
Is Annexon Inc stock a good dividend stock2025 Biggest Moves & High Return Trade Opportunity Guides - baoquankhu1.vn
Annexon Biosciences Announces Planned Retirement of Board Chairman - TipRanks
Annexon, Inc. Announces Retirement of Chairman of the Board Thomas G. Wiggans - marketscreener.com
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy - The Manila Times
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Quantisnow
Does Annexon Inc. meet Warren Buffett’s criteriaWeekly Trade Report & Low Drawdown Investment Strategies - mfd.ru
FMR LLC Reduces Stake in Annexon Inc: A Strategic Portfolio Adju - GuruFocus
Aug Decliners: What are the risks of holding Annexon IncJuly 2025 WrapUp & Safe Swing Trade Setup Alerts - baoquankhu1.vn
A Pivotal Year Ahead for Annexon’s Clinical Ambitions - AD HOC NEWS
Annexon, Inc. (NASDAQ:ANNX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Macro Review: Is Annexon Inc in a bullish channel2025 Price Targets & Low Drawdown Momentum Ideas - baoquankhu1.vn
Dow Update: Can Annexon Inc reach all time highs this yearIPO Watch & Growth Focused Stock Reports - baoquankhu1.vn
Market Recap: Will Annexon Inc benefit from government policyJuly 2025 Reactions & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Breakout Watch: Will Annexon Inc benefit from government policyDay Trade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
VIX Spike: Will CYBN stock recover after earnings2025 Support & Resistance & Detailed Earnings Play Strategies - baoquankhu1.vn
Annexon, Inc. $ANNX Stake Cut by J. Safra Sarasin Holding AG - MarketBeat
Bank of America Securities Reaffirms Their Buy Rating on Annexon Biosciences (ANNX) - The Globe and Mail
Investment Recap: Can HSCS sustain its profitability2025 Investor Takeaways & Daily Profit Maximizing Tips - baoquankhu1.vn
Analyst Downgrade: Will Annexon Inc stock benefit from M AJuly 2025 PostEarnings & Real-Time Volume Triggers - baoquankhu1.vn
Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases - Seeking Alpha
Annexon stock hits 52-week high at 7.1 USD By Investing.com - Investing.com Nigeria
Annexon stock hits 52-week high at 7.1 USD - Investing.com
Support Test: What are the risks of holding Annexon IncQuarterly Risk Review & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Annexon (NASDAQ:ANNX) Hits New 12-Month HighHere's Why - MarketBeat
Annexon Inc (NASDAQ:ANNX) Advances Complement Biology Platform - Kalkine Media
Annexon (NASDAQ:ANNX) Stock Price Up 9.5%Still a Buy? - MarketBeat
Aug Chart Watch: What are the risks of holding Annexon IncMarket Sentiment Review & Low Risk High Win Rate Picks - baoquankhu1.vn
Does Annexon’s EMA Filing For Tanruprubart Reshape The Bull Case For ANNX? - Yahoo Finance
Annexon (ANNX) Is Up 15.6% After EMA Filing For GBS Antibody Tanruprubart Has The Bull Case Changed? - simplywall.st
Levels Update: Will Annexon Inc benefit from government policyWeekly Investment Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
Assessing Annexon (ANNX) Valuation After EMA Filing For Tanruprubart In Guillain Barre Syndrome - Yahoo Finance
Annexon, Inc. (NASDAQ:ANNX) Short Interest Update - MarketBeat
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Annexon (NASDAQ:ANNX) Trading Down 5.9%Here's Why - MarketBeat
Key facts: Annexon to Submit FDA Application for Dry AMD Treatment; Key Milestones Expected in 2026 - TradingView
Alpha Buying: Managing Biotech Risk With Insider Clues - Benzinga
Annexon Maps “Pivotal” 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead - MarketBeat
Annexon, Inc. Updates on Strategic Developments and Product Pipeline - TradingView
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Annexon Biosciences stock rating reiterated by Cantor Fitzgerald - Investing.com Nigeria
Annexon (NASDAQ:ANNX) Hits New 1-Year HighWhat's Next? - MarketBeat
Pharma News: Will Annexon Inc. stock benefit from AI adoptionWeekly Market Report & Weekly Chart Analysis and Guides - Bộ Nội Vụ
Hedge Fund and Insider Trading News: Ray Dalio, Chris Rokos, Steven Cohen, Bill Ackman, Israel Englander, Scott Bessent, Citadel Investment Group, Eisler Capital, Virco Mfg Corp (VIRC), Annexon Inc (ANNX), and More - Insider Monkey
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 - The Manila Times
2.25%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):